Scandion Oncology A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 4
- Market Cap
- -
Clinical Trials
5
Active:3
Completed:0
Trial Phases
1 Phases
Phase 1:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (100.0%)Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.
Phase 1
- Conditions
- Metastatic Pancreatic AdenocarcinomaInoperable DiseaseLocally Advanced Pancreatic AdenocarcinomaLocalized Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2021-12-29
- Lead Sponsor
- Scandion Oncology A/S
- Target Recruit Count
- 18
- Registration Number
- NCT04652206
- Locations
- 🇩🇰
Aalborg University Hospital, Aalborg, Denmark
🇩🇰Odense Universitetshospital, Odense, Denmark
🇩🇪Catholic Hospital Bochum - St. Josef-Hospital, Bochum, Germany
A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Scandion Oncology A/S
- Target Recruit Count
- 35
- Registration Number
- NCT04247256
- Locations
- 🇩🇰
Aalborg Universitetshospital - Region Nordjylland, Aalborg, Denmark
🇩🇰Herlev Hospital, Herlev, Denmark
🇩🇰Hillerød Hospital, Hillerød, Denmark
News
No news found